The metabolic profiles and pharmacokinetics of pemafibrate, a novel selective peroxisome proliferator activated receptor-alpha modulator currently launched as an antidyslipidemic drug, were investigated in vitro using hepatocytes from rats, monkeys and humans and in vivo in rats and monkeys. Hepatocytes from rats, monkeys and humans all biotransformed pemafibrate to its demethylated form (M1). The bioavailabilities of pemafibrate in Sprague-Dawley rats and cynomolgus monkeys were 15% and 87%, respectively, after a single oral administration of pemafibrate (1 mg/ kg). In rat plasma, unmetabolized pemafibrate was the major form, accounting for 29% of the area under the curve (AUC) of total radioactivity. In monkey plasma, in contrast, the major circulating metabolites were M2/3 (dearylated/dicarboxylic acid forms, 15%), M4 (N-dealkylated form, 21%) and M5 (benzylic oxidative form, 9%), but pemafibrate was the notable minor form (3%). These results, in combination with the reported findings in humans, suggest that the metabolite profile of pemafibrate in plasma was different for rats and monkeys, and that monkeys could be a suitable animal model for further pharmacokinetic studies of pemafibrate in humans.
| INTRODUCTION
Pemafibrate (Figure 1 ) is a novel selective peroxisome proliferatoractivated receptor-alpha modulator (Fruchart, 2013; Raza-Iqbal et al., 2015) and has more potent and selective stimulatory effects than fenofibrate. Pemafibrate significantly decreases plasma triglyceride levels and elevates high-density lipoprotein cholesterol, with few adverse effects, in patients with dyslipidemia (Ishibashi et al., 2016 (Ishibashi et al., , 2018 . As part of their safety assessments, the comparative dispositions of fenofibrate and other hypolipidemic agents in rats, guinea pigs, dogs and humans have been reported (Weil, Caldwell, & Strolin-Benedetti, 1988 , 1990 . The benefit/risk balance of pemafibrate may provide a broader range of patients with this novel and potent treatment option for reducing triglyceride levels. However, because pemafibrate has only recently been launched as an antidyslipidemic drug, much information in terms of basic pharmacokinetic profiles remains to be elucidated.
The present study was designed to evaluate the plasma concentration-time profiles after oral and intravenous administration of pemafibrate to rats and monkeys. Further, to understand the pharmacokinetic properties of pemafibrate and its metabolites, in vitro investigations using rat, monkey and human hepatocytes were first carried out. We report herein that the metabolite profile of pemafibrate in plasma was different in rats and monkeys, and that the monkey likely represents a suitable animal model for further pharmacokinetic studies of pemafibrate in humans.
| MATERIALS AND METHODS

| Drugs and reagents
Pemafibrate and authentic metabolite standards M1-M11 were synthesized at Kowa Co., Ltd (Aichi, Japan). Free base [benzyl ring-U-14 C]pemafibrate was synthesized by Pharmaron UK (Cardiff, UK).
The radiochemical purity was > 97% and the specific activity was 2.37 GBq/mmol (4.81 MBq/mg). All other reagents were obtained from commercial sources with the highest quality.
| In vitro metabolite profiling
Cryopreserved hepatocytes from male Sprague-Dawley rats, male cynomolgus monkeys, and male and female humans (Sekisui XenoTech, Kansas City, KS, USA) were thawed and resuspended in Krebs-Henseleit buffer to give a cell density of 6 × 10 5 cells/ml, as determined by trypan blue staining. [ for 4 h at 37°C. The reaction mixtures were rinsed with 0.25 ml of Krebs-Henseleit buffer and 0.5 ml of acetonitrile and centrifuged at 12,000 × g for 5 min. Next, 0.3 ml of supernatant was evaporated under a stream of nitrogen at 40°C. After further incubation for 16 h at 37°C with β-glucuronidase/arylsulfatase from Helix pomatia (20 μl, 10,000 Fishman units/ml and 800,000 Roy units/ml, respectively, Roche Diagnostics GmbH, Mannheim, Germany) for part of the samples, samples with or without β-glucuronidase/arylsulfatase treatments were deproteinated with 50% methanol and filtered using a 0.22 μm Ultrafree-MC centrifugal filter unit (Durapore PVDF, Merck
Millipore, Burlington, MA, USA). The filtered samples then underwent high-performance liquid chromatography (HPLC) separation and were analysed using an on-line radioactivity detector. The extraction efficiencies of radioactivity from the samples were 88%-99%. Kowa and Envigo (Huntingdon, UK). Plasma samples (0.25 ml blood from rats and 1 ml from monkeys) were collected with heparin before and at 2, 5, 10 min, 0.25, 0.5, 1, 2, 4, 6, 8, 10, 24, 48 
| In vivo pharmacokinetic studies
| Quantitative analysis of pemafibrate and its metabolites
The HPLC system comprised an Alliance 2695, 2690XE or 2695XE (Table 1) . The metabolites were determined with and without β-glucuronidase/arylsulfatase treatments. High levels of conjugated and unconjugated M1 formation (17%-36%) were observed in the hepatocytes from rats, monkeys and humans tested in this study (Table 1) . However, unconjugated M1 was not seen in rat hepatocytes, suggesting that high rates of glucuronidation or sulfation occur, especially in rats. Under the current conditions, M2 and M6 were minor metabolites in hepatocytes from rats, monkeys and humans. Although M3-M5 and M11 were not identified at this stage, it should be noted that other peaks except for M1 were low.
| In vivo pharmacokinetic analysis and metabolite profiling
Plasma concentration versus time curves after [ 14 C]pemafibrate administration and pemafibrate in rats and monkeys after intravenous and oral administrations are shown in Figure 2 ; the pharmacokinetic parameters are summarized in Table 2 . After oral dosing of [ 14 C] pemafibrate (1 mg/kg) to rats, the apparent absorption ratio was 27%. The bioavailability, T max and C max values of pemafibrate were 15%, 1 h and 34 ng/ml, respectively. The AUC of total radioactivity (365 ng eq.·h/ml) was 2.2-fold that of pemafibrate (168 ng·h/ml). In contrast, after oral dosing of [ 14 C]pemafibrate to monkeys, the apparent absorption ratio was 74%. The bioavailability, T max and C max values of pemafibrate were 87%, 2 h and 694 ng/ml, respectively. The AUC of total radioactivity (12,500 ng eq.·h/ml) was 8.0-fold that of pemafibrate (1560 ng/ml).
Representative chromatograms for the metabolites of [
pemafibrate in plasma from rats and monkeys after a single oral administration are shown in Figure 3 . Unmetabolized pemafibrate was the major radioactive component in rats (Figure 3a ), but only a minor component in monkeys (Figure 3b ), accounting for 29% and 1.23 (< 1) < 1 (< 1) < 1 (< 1) < 1 (< 1) 5.34 (< 1) M8 5.83 (< 1) 1.47 (< 1) < 1 (< 1) < 1 (< 1) 1.17 (< 1) M9 8.49 (< 1) 2.06 (< 1) < 1 (< 1) < 1 (< 1) 2.34 (< 1) ]Pemafibrate (5 μmol/l) was incubated with hepatocytes from rats, monkeys and humans for 4 h. The metabolites were determined with or without β-glucuronidase/arylsulfatase treatments. The values in parentheses are the ratios to total radioactivity without β-glucuronidase/arylsulfatase treatments. M3-M5 and M11 were not tested. Because M3-M5 and M11 were separated from major metabolite M1, it was assumed that the generated M3-M5 and M11 levels would be low.
FIGURE 2 Mean plasma concentration-time curves of total radioactivity (circles) and pemafibrate (triangles) in rats (a) and monkeys (b) after both intravenous and oral doses. [ 14 C] Pemafibrate and pemafibrate were administered intravenously (i.v.) and orally (p. o.) to overnight-fasted male Sprague-Dawley rats and to male cynomolgus monkeys. Mean ± SD for three animals are shown 3%, respectively, of the AUC of the total radioactivities. The calculated metabolic profiles of pemafibrate in plasma and feces are shown in Table 3 . The metabolites M2/3, M4 and M5 in rat plasma accounted for 1%, 5% and 3% of the radioactivity, respectively. In rat feces, pemafibrate, M1, M2 and M6 accounted for 40%, 29%, 5% and 7% of the dose, respectively. In contrast, in monkeys, metabolites M1, M2/3, M4, and M5 accounted for 1%, 15%, 21% and 9% of the radioactivity, respectively, in plasma. In monkey feces, M1, M2/3, M4, M5 and M6 accounted for 10%, 14%, 2%, 3% and 4% of the dose, respectively.
| DISCUSSION
The prediction of metabolites in human plasma is important in the research and development of drug candidates because the major metabolites in humans need to undergo toxicity evaluation using C]Pemafibrate or pemafibrate was administered intravenously in physiological saline containing sodium hydroxide and ethanol (5%, v/v, monkey only) or orally in 0.5% methylcellulose solution to overnight-fasted male Sprague-Dawley rats and male cynomolgus monkeys. C max , observed peak plasma concentration after oral dosing; T max , time to reach C max ; F a , apparent absorption ratio; F, bioavailability; N.D., not determined, N.C., not calculated. F a and F was determined by a relative comparison of the mean AUC values associated with the intravenous and the oral doses. T max data are medians. The other parameters are means (± SD) for 2 or 3 animals. Urinary excretion ratio was 1.9 ± 0.4. bUrinary excretion ratio, aqueous cage wash, and cage debris were 11.0 ± 5.5, 3.9 ± 1.4 and 14.7 ± 7.7, respectively. N.D., not detected; N.T., not tested. Data are means (± SD) for 2 or 3 animals.
methods of predicting metabolites. However, such approaches have limitations: in particular, the prediction of secondary metabolites is known to be difficult (Dalvie et al., 2009) . Moreover, in vitro systems may predict potential metabolites but might not predict circulating metabolites.
The proposed metabolic pathways of pemafibrate in rats, monkeys and humans are summarized in Figure 4 . In the present study, based on the results using hepatocytes, the production of M1 from pemafibrate was presumed to be a major pathway, with no species differences among the animals tested. It has been reported that the met- , 2018) . Moreover, the current study revealed that M2/3, M4 and M5 were hardly detected in rat plasma, as shown in Figure 3a . In contrast, in monkey plasma, M2/3, M4 and M5 were detected at levels equal to or higher than those reported in humans. It was able to be assumed that the plasma exposures of M1 would be low in all species tested because the M1 and/or M1 conjugate were readily excreted into bile. Moreover, because M1 was detected in feces from rats and monkeys in this study (Table 3) and from humans, as reported (29%, 10% and~50% of dose, respectively), it is possible that the M1 conjugate can be deconjugated by intestinal bacteria after being excreted in bile as a conjugate. It is likely that M2/3, M4 and M5 will be produced or distributed to plasma in monkeys and humans. M3, M4 and M5 are possibly secondary metabolites, which could be difficult to predict in in vitro systems. Recently, chimeric mice with humanized livers have demonstrated their usefulness in predicting circulating human-specific or disproportionate metabolites (Kamimura et al., 2017) . The high circulating concentrations of metabolites M2/3, M4 and M5 in humans may be reproducible in these mice.
The species-dependent metabolism of fenofibrate has also been reported (Mogi, Abe, Hayashi & Tsutsumi, 1995) . Fenofibric acid (FA, the active metabolite) and reduced FA (RFA) are mainly detected in plasma from both rats and dogs, but the concentration ratio of RFA to total radioactivity is almost 3-fold higher in dogs than in rats (rat/ dog: < 19.0%/56.2%-66.8% of total radioactivity). The species differences in the plasma metabolic profiles are found in fenofibrate, just as they are in pemafibrate. However, the species differences in the excretion ratios of fenofibrate, FA and RFA, which are major components in urine and feces, are small (rat/dog: not detected, 5.4%/ 2.0%, and 7.2%/9.3% of dose in urine, and 7.8%/5.6%, 20.7%/ 22.6%, and 5.5%/9.1% of dose in feces). As a result, the metabolic profiles of fenofibrate are suggested to be similar in rats and dogs.
These findings suggest that the species differences of disposition and/or excretion can be attributed to the species differences in the plasma metabolic profiles of both pemafibrate and fenofibrate.
Recently, species differences in the substrate specificity, tissue distribution and relative abundance of transporters have been reported (Chu, Bleasby, & Evers, 2013) . However, it has been suggested that the substrate and inhibitor profiles in hepatic uptake transporters
[organic anion-transporting polypeptides (OATPs)] are similar in cynomolgus monkeys and humans (Shen et al., 2013) . Moreover, cynomolgus monkeys are useful to support the assessment of potential clinical drug interactions involving hepatic uptake transporters (Takahashi FIGURE 4 Proposed metabolic pathways of pemafibrate in rats, monkeys and humans. Also indicated are the ratios of AUCs to total radioactivity in human (H), monkey (M) and rat (R). In human, M4 includes glucuronide of M3 et al., 2013) . Therefore, we believe that the plasma metabolic profiles of pemafibrate are similar in monkeys and humans because the disposition and/or excretion are similar in the two species.
In conclusion, the metabolite profile of pemafibrate in plasma was different in rats and monkeys, as summarized in Figure 4 . The present results provide a better understanding of the pharmacokinetic properties of pemafibrate and help to clarify the species differences in pemafibrate metabolism. We suggest that monkeys are likely to be a suitable animal model for further pharmacokinetic studies of pemafibrate in humans.
